Integrating molecular, lifestyle and clinical epidemiology to study risk factors for initiation and progression of cancer.
Investigating pathways of circadian rhythm disruption as a risk factor for prostate cancer.
Assessing the clinical utility of using tumor genomic markers for GU cancer outcomes.